Matches in SemOpenAlex for { <https://semopenalex.org/work/W2223738955> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2223738955 endingPage "e13508" @default.
- W2223738955 startingPage "e13508" @default.
- W2223738955 abstract "e13508 Background: Liposomal doxorubicin (D) and bevacizumab (A) are active drugs in multiple malignancies. Unfortunately, resistance mechanisms have been described for each that limit their efficacy following repeated exposure. These include aberrant activation of alternate signaling pathways, such as PI3K/AKT/mTOR and upregulation of hypoxia inducible factor (HIF-1α). We therefore added temsirolimus (T), an agent known to inhibit mTOR and to downregulate HIF-1α, to the combination of D and A. The objectives of this trial were to assess the safety of this combination, obtain preliminary efficacy data and to identify biologic correlates for treatment response. Methods: D, A and T were administered intravenously on a 21 day cycle. D, A and T were given day 1, and T was administered alone weeks 2 and 3. A standard 3+3 trial design was used for dose escalation; 6 dose levels are planned. Patient serum and biopsies were also collected pre- and post-treatment for batched analysis to assess biologic response correlates. Results: 6/12 treated patients are evaluable (remaining patients have not yet completed 1st restaging). 5 patients are male; median age (all patients) 53, range 12 to 59. Median number of prior treatments = 5, range 2 - 8. At first restaging, 2/2 patients with endometrial cancer were found to have ≥ 25% decrease in tumor size (RECIST), and one patient with colorectal carcinoma had a 15% decrease. 1 patient had stable disease. One of the patients with endometrial cancer and extensive intra-abdominal disease who showed rapid tumor regression (≥ 25% decrease at 2 months) developed an entero-colonic fistula, and chose hospice care. Grade 2 stomatitis and fatigue (CTCAEv3)have also been seen. The current doses being used are 20mg/m2 of D and 5mg/m2 of A every 21 days, and 25mg of T every 7 days (dose level 3). Conclusions: Preliminary data indicate that the combination of D, A and T has anti-tumor activity and is well tolerated at the doses used. Patients with intra-abdominal disease who experience rapid tumor regression may be at risk for fistula formation. Biomarker analysis for modulation of the mTOR signal (via PI3K mutations or other aberrations) and the HIF-1α pathway is ongoing. No significant financial relationships to disclose." @default.
- W2223738955 created "2016-06-24" @default.
- W2223738955 creator A5005436649 @default.
- W2223738955 creator A5009234043 @default.
- W2223738955 creator A5026095888 @default.
- W2223738955 creator A5036211173 @default.
- W2223738955 creator A5039023986 @default.
- W2223738955 creator A5053460346 @default.
- W2223738955 creator A5053481267 @default.
- W2223738955 creator A5056279465 @default.
- W2223738955 creator A5060086956 @default.
- W2223738955 creator A5069777765 @default.
- W2223738955 date "2009-05-20" @default.
- W2223738955 modified "2023-09-22" @default.
- W2223738955 title "A phase I trial of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) in advanced malignancy" @default.
- W2223738955 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e13508" @default.
- W2223738955 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27961272" @default.
- W2223738955 hasPublicationYear "2009" @default.
- W2223738955 type Work @default.
- W2223738955 sameAs 2223738955 @default.
- W2223738955 citedByCount "2" @default.
- W2223738955 countsByYear W22237389552012 @default.
- W2223738955 crossrefType "journal-article" @default.
- W2223738955 hasAuthorship W2223738955A5005436649 @default.
- W2223738955 hasAuthorship W2223738955A5009234043 @default.
- W2223738955 hasAuthorship W2223738955A5026095888 @default.
- W2223738955 hasAuthorship W2223738955A5036211173 @default.
- W2223738955 hasAuthorship W2223738955A5039023986 @default.
- W2223738955 hasAuthorship W2223738955A5053460346 @default.
- W2223738955 hasAuthorship W2223738955A5053481267 @default.
- W2223738955 hasAuthorship W2223738955A5056279465 @default.
- W2223738955 hasAuthorship W2223738955A5060086956 @default.
- W2223738955 hasAuthorship W2223738955A5069777765 @default.
- W2223738955 hasConcept C126322002 @default.
- W2223738955 hasConcept C142724271 @default.
- W2223738955 hasConcept C143998085 @default.
- W2223738955 hasConcept C183713625 @default.
- W2223738955 hasConcept C185592680 @default.
- W2223738955 hasConcept C190283241 @default.
- W2223738955 hasConcept C2776694085 @default.
- W2223738955 hasConcept C2776820818 @default.
- W2223738955 hasConcept C2777802072 @default.
- W2223738955 hasConcept C2778256501 @default.
- W2223738955 hasConcept C2778629024 @default.
- W2223738955 hasConcept C2779399171 @default.
- W2223738955 hasConcept C2780752271 @default.
- W2223738955 hasConcept C2781303535 @default.
- W2223738955 hasConcept C55493867 @default.
- W2223738955 hasConcept C71924100 @default.
- W2223738955 hasConcept C86554907 @default.
- W2223738955 hasConceptScore W2223738955C126322002 @default.
- W2223738955 hasConceptScore W2223738955C142724271 @default.
- W2223738955 hasConceptScore W2223738955C143998085 @default.
- W2223738955 hasConceptScore W2223738955C183713625 @default.
- W2223738955 hasConceptScore W2223738955C185592680 @default.
- W2223738955 hasConceptScore W2223738955C190283241 @default.
- W2223738955 hasConceptScore W2223738955C2776694085 @default.
- W2223738955 hasConceptScore W2223738955C2776820818 @default.
- W2223738955 hasConceptScore W2223738955C2777802072 @default.
- W2223738955 hasConceptScore W2223738955C2778256501 @default.
- W2223738955 hasConceptScore W2223738955C2778629024 @default.
- W2223738955 hasConceptScore W2223738955C2779399171 @default.
- W2223738955 hasConceptScore W2223738955C2780752271 @default.
- W2223738955 hasConceptScore W2223738955C2781303535 @default.
- W2223738955 hasConceptScore W2223738955C55493867 @default.
- W2223738955 hasConceptScore W2223738955C71924100 @default.
- W2223738955 hasConceptScore W2223738955C86554907 @default.
- W2223738955 hasIssue "15_suppl" @default.
- W2223738955 hasLocation W22237389551 @default.
- W2223738955 hasOpenAccess W2223738955 @default.
- W2223738955 hasPrimaryLocation W22237389551 @default.
- W2223738955 hasRelatedWork W1540317073 @default.
- W2223738955 hasRelatedWork W1878218305 @default.
- W2223738955 hasRelatedWork W2032051122 @default.
- W2223738955 hasRelatedWork W2037837794 @default.
- W2223738955 hasRelatedWork W2063672847 @default.
- W2223738955 hasRelatedWork W2122132792 @default.
- W2223738955 hasRelatedWork W2137381953 @default.
- W2223738955 hasRelatedWork W2154171266 @default.
- W2223738955 hasRelatedWork W2601626987 @default.
- W2223738955 hasRelatedWork W3128010851 @default.
- W2223738955 hasVolume "27" @default.
- W2223738955 isParatext "false" @default.
- W2223738955 isRetracted "false" @default.
- W2223738955 magId "2223738955" @default.
- W2223738955 workType "article" @default.